Regarding the potential of other PGs to treat MS in models of EAE, it has been shown that activation of 15d-PGJ2’s receptor PPARγ (Table 1) by either 15-PGJ2 or Ciglitazone (a selective PPARγ ligand) can inhibit disease progression in EAE mice. Here, PPARG is linked to myeloid sarcoma.